199 related articles for article (PubMed ID: 22333583)
1. Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.
Murphy RF; Komlodi-Pasztor E; Robey R; Balis FM; Farrell NP; Fojo T
Cell Cycle; 2012 Mar; 11(5):963-73. PubMed ID: 22333583
[TBL] [Abstract][Full Text] [Related]
2. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
3. Modulation of drug activation profiles through carboxylate ligand modification in cytotoxic trans-platinum planar amine compounds.
Benedetti BT; Quintal S; Farrell NP
Dalton Trans; 2011 Nov; 40(41):10983-8. PubMed ID: 21918760
[TBL] [Abstract][Full Text] [Related]
4. Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y.
Donzelli E; Carfì M; Miloso M; Strada A; Galbiati S; Bayssas M; Griffon-Etienne G; Cavaletti G; Petruccioli MG; Tredici G
J Neurooncol; 2004; 67(1-2):65-73. PubMed ID: 15072449
[TBL] [Abstract][Full Text] [Related]
5. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
[TBL] [Abstract][Full Text] [Related]
6. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic activities, cellular uptake, gene regulation, and optical imaging of novel platinum(II) complexes.
Gao J; Liu YG; Zingaro RA
Chem Res Toxicol; 2009 Oct; 22(10):1705-12. PubMed ID: 19694485
[TBL] [Abstract][Full Text] [Related]
8. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research.
Vekris A; Meynard D; Haaz MC; Bayssas M; Bonnet J; Robert J
Cancer Res; 2004 Jan; 64(1):356-62. PubMed ID: 14729645
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity and cellular accumulation of a new cis-diammineplatinum (II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II).
Viale M; Cafaggi S; Parodi B; Esposito M
Cancer Chemother Pharmacol; 1995; 35(5):371-6. PubMed ID: 7850917
[TBL] [Abstract][Full Text] [Related]
11. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
12. Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.
Xie X; He G; Siddik ZH
Mol Cancer Res; 2017 Mar; 15(3):328-339. PubMed ID: 28031409
[TBL] [Abstract][Full Text] [Related]
13. Organic cation transporters are determinants of oxaliplatin cytotoxicity.
Zhang S; Lovejoy KS; Shima JE; Lagpacan LL; Shu Y; Lapuk A; Chen Y; Komori T; Gray JW; Chen X; Lippard SJ; Giacomini KM
Cancer Res; 2006 Sep; 66(17):8847-57. PubMed ID: 16951202
[TBL] [Abstract][Full Text] [Related]
14. Antitumor active trans‑platinum complexes through metabolic stability and enhanced cellular accumulation.
Menon V; Katner SJ; Lee DE; Peterson EJ; Koblinski JE; Farrell NP
J Inorg Biochem; 2024 Mar; 252():112475. PubMed ID: 38199050
[TBL] [Abstract][Full Text] [Related]
15. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
Bhatt M; Ivan C; Xie X; Siddik ZH
Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466
[TBL] [Abstract][Full Text] [Related]
16. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
18. Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.
Kasparkova J; Fojta M; Farrell N; Brabec V
Nucleic Acids Res; 2004; 32(18):5546-52. PubMed ID: 15486204
[TBL] [Abstract][Full Text] [Related]
19. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
